StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
39
Publishing Date
2023 - 12 - 21
1
2023 - 11 - 28
1
2023 - 10 - 30
1
2023 - 09 - 22
1
2023 - 09 - 19
1
2023 - 07 - 18
1
2023 - 05 - 16
1
2023 - 04 - 27
1
2023 - 01 - 17
1
2023 - 01 - 04
1
2022 - 12 - 22
1
2022 - 08 - 25
1
2022 - 06 - 09
1
2022 - 05 - 19
1
2022 - 05 - 11
1
2022 - 04 - 25
1
2022 - 03 - 02
1
2022 - 03 - 01
1
2022 - 02 - 16
1
2022 - 02 - 15
1
2022 - 01 - 18
1
2021 - 12 - 13
1
2021 - 09 - 28
1
2021 - 09 - 21
1
2021 - 08 - 26
1
2021 - 08 - 09
1
2021 - 08 - 06
1
2021 - 07 - 14
1
2021 - 06 - 22
1
2021 - 06 - 08
1
2021 - 06 - 01
1
2021 - 05 - 24
1
2021 - 04 - 06
1
2021 - 03 - 29
1
2021 - 03 - 10
1
2021 - 02 - 11
1
2021 - 01 - 28
1
2021 - 01 - 21
1
2020 - 12 - 04
1
Sector
Commercial services
1
Finance
1
Health services
2
Health technology
39
Manufacturing
1
Technology services
1
Tags
Agreement
25
Alliances
39
Alzheimer's
23
Alzheimer’s
23
Antibody
51
Approval
46
Biomidwest
40
Biopharma
36
Biotech-bay
24
Biotechnology
25
Cancer
139
China
47
Chinese
28
Clinical-trials-phase-iii
32
Collaboration
71
Companies
51
Conference
76
Covid
62
Covid-19
48
Designation
22
Diabetes
57
Disease
89
Drug
105
Earnings
45
Events
32
Expected
24
Fda
71
Financial
65
Financial results
42
Global
149
Growth
108
Health
30
Heart
23
Insulin
37
Iot
23
License
26
Market
305
Meeting
26
Money
34
N/a
1119
Obesity
28
People
70
Pharma
35
Pharmaceutical
24
Phase 1
24
Phase 2
34
Phase 3
47
Positive
30
Report
140
Research
148
Results
203
Risk
24
Study
74
Technology
27
Therapeutics
138
Therapy
88
Tirzepatide
24
Treatment
175
Trial
116
Update
33
Entities
2seventy bio, inc.
5
908 devices inc
5
Abbvie inc.
19
Abcellera biologics inc
8
Aditx therapeutics, inc.
6
Agilent technologies, inc.
8
Amgen inc.
7
Astellas pharma inc
6
Astrazeneca plc
24
Beigene, ltd.
9
Bio-techne corp
11
Biogen inc.
12
Bridgebio pharma, inc.
9
Bristol-myers squibb company
21
Bruker corporation
5
Casi pharmaceuticals, inc.
5
Cerus corporation
5
Charles river laboratories international, inc.
13
Clovis oncology, inc.
5
Coherus biosciences, inc.
6
Curevac n.v.
6
Cybin inc
7
Eli lilly and company
39
Evotec se
17
Evotec se - adr
14
Exelixis, inc.
6
Fortress biotech, inc.
5
Genmab a/s
5
Gilead sciences, inc.
22
Glaxosmithkline plc
5
Guardant health, inc.
5
Horizon therapeutics public limited company
7
I-mab
10
Illumina, inc.
8
Incyte corporation
9
Johnson & johnson
52
Laboratory corporation of america holdings
6
Lineage cell therapeutics, inc.
7
Merck & company, inc.
17
Moderna, inc.
20
Nektar therapeutics
10
Neogenomics, inc.
6
Novocure limited
6
Orange
15
Pfizer, inc.
8
Premier, inc.
6
Pressure biosciences, inc.
6
Qiagen n.v.
8
Quest diagnostics incorporated
9
Regeneron pharmaceuticals, inc.
6
Sanofi
89
Simulations plus, inc.
6
Takeda pharmaceutical company limited
16
Teva pharmaceutical industries ltd
7
Thermo fisher scientific inc
20
Twist bioscience corporation
27
Veeva systems inc.
6
Vertex pharmaceuticals incorporated
6
Virpax pharmaceuticals inc
7
Xencor, inc.
7
Symbols
ABCL
3
ACRS
1
ALNY
1
ALXO
1
ARE
1
BOLT
1
EVO
1
EVOTF
1
FHTX
1
GDRX
1
GSK
1
IMGN
1
INCY
3
JNJ
1
LLY
39
NEO
1
NVO
1
PRQR
1
QTRX
1
SNY
1
UNH
1
VIR
1
Exchanges
Nasdaq
18
Nyse
39
Crawled Date
2023 - 12 - 21
1
2023 - 11 - 28
1
2023 - 10 - 30
1
2023 - 09 - 22
1
2023 - 09 - 19
1
2023 - 07 - 18
1
2023 - 05 - 16
1
2023 - 04 - 27
1
2023 - 01 - 17
1
2023 - 01 - 04
1
2022 - 12 - 22
1
2022 - 08 - 25
1
2022 - 06 - 09
1
2022 - 05 - 19
1
2022 - 05 - 11
1
2022 - 04 - 25
1
2022 - 03 - 02
1
2022 - 03 - 01
1
2022 - 02 - 16
1
2022 - 02 - 15
1
2022 - 01 - 18
1
2021 - 12 - 13
1
2021 - 09 - 28
1
2021 - 09 - 21
1
2021 - 08 - 26
1
2021 - 08 - 09
1
2021 - 08 - 06
1
2021 - 07 - 14
1
2021 - 06 - 22
1
2021 - 06 - 08
1
2021 - 06 - 01
1
2021 - 05 - 24
1
2021 - 04 - 06
1
2021 - 03 - 29
1
2021 - 03 - 10
1
2021 - 02 - 11
1
2021 - 01 - 28
1
2021 - 01 - 21
1
2020 - 12 - 04
1
Crawled Time
09:00
1
11:00
1
12:00
4
13:00
7
14:00
3
14:15
1
15:00
8
15:20
1
15:30
1
16:00
2
17:00
1
18:00
2
19:00
2
21:00
3
23:00
2
Source
www.biospace.com
39
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Alliances
entities :
Eli lilly and company
save search
Fauna Bio Announces Strategic Collaboration with Lilly to Discover Novel Obesity Targets Using Convergence™ AI Platform
Published:
2023-12-21
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
31.67%
|
O:
0.21%
H:
0.63%
C:
0.1%
obesity
collaboration
platform
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
Published:
2023-11-28
(Crawled : 21:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
26.92%
|
O:
0.05%
H:
0.0%
C:
0.0%
ARE
A
|
$116.45
-0.46%
-0.12%
610K
|
Finance
|
11.4%
|
O:
-0.19%
H:
3.05%
C:
2.77%
partnership
Redwire Announces First Spaceflight Mission for New Cutting-Edge Pharmaceutical Drug Development Lab, Partnering with Eli Lilly and Company to Expand Space Research to Study Heart Disease and Diabetes
Published:
2023-10-30
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
32.98%
|
O:
0.69%
H:
0.0%
C:
0.0%
drug
disease
company
space
research
heart
diabetes
study
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Published:
2023-09-22
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
32.8%
|
O:
-2.93%
H:
1.22%
C:
0.32%
jardiance
fda
disease
kidney
treatment
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
Published:
2023-09-19
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
31.42%
|
O:
0.06%
H:
1.19%
C:
0.58%
bbi-355
verzenio
tumors
collaboration
trial
agreement
Allen Institute for Immunology partners with Lilly to better understand autoimmune disease
Published:
2023-07-18
(Crawled : 18:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
67.9%
|
O:
-0.04%
H:
1.43%
C:
0.95%
institute
disease
immunology
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
Published:
2023-05-16
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
72.79%
|
O:
-0.07%
H:
0.98%
C:
0.56%
genetic
wholly
collaboration
neurological
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
Published:
2023-04-27
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
99.53%
|
O:
3.98%
H:
1.86%
C:
-0.23%
zb-106
potential
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Published:
2023-01-17
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
107.61%
|
O:
0.0%
H:
0.11%
C:
-1.07%
therapeutics
migraine
china
Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases
Published:
2023-01-04
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
105.7%
|
O:
-0.1%
H:
0.68%
C:
-0.42%
wholly
collaboration
Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology
Published:
2022-12-22
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
104.01%
|
O:
-0.19%
H:
0.66%
C:
-0.55%
PRQR
|
$1.92
-4.0%
-4.17%
200K
|
Health Technology
|
15.15%
|
O:
64.85%
H:
13.97%
C:
-0.74%
axiomer
technology
agreement
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
Published:
2022-08-25
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
135.45%
|
O:
0.54%
H:
0.86%
C:
0.79%
ACRS
|
$1.23
0.82%
0.81%
560K
|
Health Technology
|
-92.89%
|
O:
1.27%
H:
3.94%
C:
3.94%
patent
license
therapeutics
agreement
Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing
Published:
2022-06-09
(Crawled : 15:20)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
139.49%
|
O:
-0.6%
H:
0.1%
C:
-2.68%
collaboration
genomic
test
Iterative Scopes to Present Three Abstracts on Artificial Intelligence Applications for GI Endoscopy at DDW 2022
Published:
2022-05-19
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
149.33%
|
O:
-2.5%
H:
0.0%
C:
-2.49%
endoscopy
FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published:
2022-05-11
(Crawled : 16:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
157.18%
|
O:
-3.03%
H:
0.0%
C:
0.0%
covid-19
fda
olumiant
covid
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
Published:
2022-04-25
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
160.48%
|
O:
-3.29%
H:
2.58%
C:
2.31%
NEO
|
$13.68
-1.23%
-1.24%
560K
|
Health Services
|
20.85%
|
O:
-2.83%
H:
2.64%
C:
2.27%
partnership
program
cancer
test
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company
Published:
2022-03-02
(Crawled : 18:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
203.11%
|
O:
0.79%
H:
0.0%
C:
0.0%
ALXO
|
$16.08
10.97%
9.89%
2M
|
Commercial Services
|
-20.12%
|
O:
0.0%
H:
4.13%
C:
3.97%
aspen-06
treatment
phase 2
phase 2/3
collaboration
cancer
initiated
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published:
2022-03-01
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
206.93%
|
O:
1.26%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-22.25%
|
O:
0.44%
H:
2.1%
C:
0.88%
heart
therapeutics
cel
lung cancer
positive
cancer
designation
Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence
Published:
2022-02-16
(Crawled : 15:30)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
207.89%
|
O:
-0.52%
H:
1.83%
C:
1.24%
risk
cancer
breast cancer
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
Published:
2022-02-15
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
219.9%
|
O:
0.84%
H:
3.44%
C:
3.04%
IMGN
|
$31.23
0.03%
49M
|
Health Technology
|
463.9%
|
O:
2.53%
H:
5.43%
C:
2.11%
license
platform
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.